MRNA Quote, Financials, Valuation and Earnings

Eli Lilly and has a net margin of 0.7% compared to Moderna's net margin of 8.48%. Moderna's return on equity of -17.44% beat Eli Lilly and's return on equity of 66.4%.

Moderna has a consensus price target of $127.09, signalling upside risk potential of 84.23%. On the other hand Eli Lilly and has an analysts' consensus of $984.05 which suggests that it could grow by 23.68%. Given that Moderna has higher upside potential than Eli Lilly and, analysts believe Moderna is more attractive than Eli Lilly and.

Moderna has a beta of 1.582, which suggesting that the stock is 58.238% more volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.409, suggesting its less volatile than the S&P 500 by 59.07%.

Moderna has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly and offers a yield of 0.65% to investors and pays a quarterly dividend of $1.30 per share. Moderna pays -- of its earnings as a dividend. Eli Lilly and pays out 77.65% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Moderna quarterly revenues are $1.9B, which are smaller than Eli Lilly and quarterly revenues of $11.4B. Moderna's net income of $13M is lower than Eli Lilly and's net income of $970.3M. Notably, Moderna's price-to-earnings ratio is -- while Eli Lilly and's PE ratio is 86.02x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Moderna is 3.08x versus 17.61x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

Merck & has a net margin of 0.7% compared to Moderna's net margin of 18.95%. Moderna's return on equity of -17.44% beat Merck &'s return on equity of 29.26%.

Moderna has a consensus price target of $127.09, signalling upside risk potential of 84.23%. On the other hand Merck & has an analysts' consensus of $128.73 which suggests that it could grow by 29.44%. Given that Moderna has higher upside potential than Merck &, analysts believe Moderna is more attractive than Merck &.

Moderna has a beta of 1.582, which suggesting that the stock is 58.238% more volatile than S&P 500. In comparison Merck & has a beta of 0.393, suggesting its less volatile than the S&P 500 by 60.746%.

Moderna has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & offers a yield of 3.14% to investors and pays a quarterly dividend of $0.81 per share. Moderna pays -- of its earnings as a dividend. Merck & pays out 2039.73% of its earnings as a dividend.

Moderna quarterly revenues are $1.9B, which are smaller than Merck & quarterly revenues of $16.7B. Moderna's net income of $13M is lower than Merck &'s net income of $3.2B. Notably, Moderna's price-to-earnings ratio is -- while Merck &'s PE ratio is 20.85x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Moderna is 3.08x versus 4.00x for Merck &. Usually stocks with elevated PS ratios are considered overvalued.

Novavax has a net margin of 0.7% compared to Moderna's net margin of -143.53%. Moderna's return on equity of -17.44% beat Novavax's return on equity of --.

Moderna has a consensus price target of $127.09, signalling upside risk potential of 84.23%. On the other hand Novavax has an analysts' consensus of $16.00 which suggests that it could grow by 88.01%. Given that Novavax has higher upside potential than Moderna, analysts believe Novavax is more attractive than Moderna.

Moderna has a beta of 1.582, which suggesting that the stock is 58.238% more volatile than S&P 500. In comparison Novavax has a beta of 2.017, suggesting its more volatile than the S&P 500 by 101.749%.

Moderna has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Novavax offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Moderna pays -- of its earnings as a dividend. Novavax pays out -- of its earnings as a dividend.

Moderna quarterly revenues are $1.9B, which are larger than Novavax quarterly revenues of $84.5M. Moderna's net income of $13M is higher than Novavax's net income of -$121.3M. Notably, Moderna's price-to-earnings ratio is -- while Novavax's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Moderna is 3.08x versus 1.48x for Novavax. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer has a net margin of 0.7% compared to Moderna's net margin of 25.23%. Moderna's return on equity of -17.44% beat Pfizer's return on equity of 4.63%.

Moderna has a consensus price target of $127.09, signalling upside risk potential of 84.23%. On the other hand Pfizer has an analysts' consensus of $31.86 which suggests that it could grow by 19.16%. Given that Moderna has higher upside potential than Pfizer, analysts believe Moderna is more attractive than Pfizer.

Moderna has a beta of 1.582, which suggesting that the stock is 58.238% more volatile than S&P 500. In comparison Pfizer has a beta of 0.653, suggesting its less volatile than the S&P 500 by 34.739%.

Moderna has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer offers a yield of 6.28% to investors and pays a quarterly dividend of $0.42 per share. Moderna pays -- of its earnings as a dividend. Pfizer pays out 436.39% of its earnings as a dividend.

Moderna quarterly revenues are $1.9B, which are smaller than Pfizer quarterly revenues of $17.7B. Moderna's net income of $13M is lower than Pfizer's net income of $4.5B. Notably, Moderna's price-to-earnings ratio is -- while Pfizer's PE ratio is 36.14x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Moderna is 3.08x versus 2.56x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.